Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Senate panel moves meth bill

This article was originally published in The Tan Sheet

Executive Summary

The Senate Judiciary Committee approves legislation to prevent mass purchases of methamphetamine precursors by facilitating use of electronic logbooks in pharmacies through state and local government grants, according to bill co-sponsor Sen. Chuck Grassley, R-Iowa. The Methamphetamine Production Prevention Act of 2007, S. 1276, aims to stop "smurfing" - buying nonprescription, pseudoephedrine-containing cold or allergy remedies in small quantities at multiple pharmacies - by making "electronic logbook systems far more cost-effective without hurting law enforcement efforts," Grassley says in a Sept. 11 release. The bill was introduced in May 2007 by Sen. Dick Durbin, D-Ill., to add the electronic logbook provision omitted by 2006's Combat Meth Act (1"The Tan Sheet" May 7, 2007, p. 3). A companion bill, H.R. 2747, has not moved since being referred to a House Judiciary subcommittee in July 2007 (2"The Tan Sheet" June 25, 2007, In Brief). Several states, including Arkansas and Iowa, have introduced their own e-tracking systems (3"The Tan Sheet" June 9, 2008, In Brief)

You may also be interested in...

Durbin Introduces Pseudoephedrine Electronic Log Bill To Fight Smurfing

A bill introduced in Congress May 3 funds the creation of electronic databases to record pseudoephedrine purchases, in an effort to improve enforcement of existing methamphetamine precursor control laws

Boehringer Ingelheim, Gubra Enter Third Obesity Deal

The independent, family-controlled German group has signed a third R&D pact with Danish biotech Gubra to develop poly-agonist peptides for obesity.

First Phase III Data For Inovio's Immunotherapy VGX-3100 Encouraging In Cervical Dysplasia

Inovio Pharmaceuticals has reported promising initial data from its first Phase III study of its electrical current-driven DNA plasmid-based immunotherapy, VGX-3100, in virus-associated cervical dysplasia; it is heading a small group of companies evaluating novel therapies in the condition, which often advances to cancer.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts